Brought to you by 
Acadia Pharmaceuticals nets $282mm in public offering
08 Jan 2016
Executive Summary
Acadia Pharmaceuticals Inc. (develops drugs for neurological and psychiatric disorders) netted $282 mm in a public offering of 10.3mm shares at $29. The company will use the proceeds to fund commercialization of Nuplazid (pimavanserin)--accepted for priority review by the FDA with a PDUFA date of May 1, 2016 in Parkinson’s disease psychosis--and continued development of pimavanserin in additional indications; the candidate is also currently in Phase II for schizophrenia.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acadia Pharmaceuticals nets $282mm in public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice